Introduction
============

Until recently, the classification of lung cancer into two groups, non-small cell lung cancer (NSCLC) and small cell lung cancer, was adequate for selection of appropriate therapy. However, the use of new therapeutic agents for NSCLC requires definite knowledge of histological subtype. In particular, it is important to discriminate between squamous cell carcinoma and non-squamous cell carcinoma in NSCLC. In recent phase III clinical trials, pemetrexed showed a superior effect in non-squamous cell carcinoma, such as adenocarcinoma and large cell carcinoma, than in squamous cell carcinoma[@B1],[@B2]. Bevacizumab is not recommended for treatment of squamous cell carcinoma, due to the higher frequency of pulmonary hemorrhage in this histologic subtype[@B3],[@B4].

The epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) gefitinib and erlotinib produce a dramatic response when used as a first-line therapy in NSCLCs carrying an activating *EGFR* mutation[@B5],[@B6]. The anaplastic lymphoma kinase (ALK) inhibitor, crizotinib, is effective in NSCLCs with rearrangement of *ALK*[@B7]. Moreover, the molecular markers for targeting of these agents, *EGFR* mutations and *ALK* rearrangements, are primarily found in adenocarcinoma[@B5]-[@B7]. Therefore, the histologic subtype of NSCLC is an important consideration, not only in selecting cytotoxic chemotherapeutic agents, but also to target molecular analysis tests.

Approximately 70% of patients with lung cancer are diagnosed using small biopsy or cytology specimens, as they present with unresectable, advanced stage disease[@B8],[@B9]. Thus, it is important to be able to diagnose lung cancer and confirm histologic subtypes using small specimens.

While the amount of specimen required for histologic subtyping and molecular predictive testing has increased, the sample size obtained from patients is frequently insufficient. Therefore, it is critical to optimize the use of tissue samples for diagnostic and predictive examination[@B10],[@B11].

This article will review strategies for tissue acquisition, pathology approach, histologic subtyping, specimen requirement, and molecular analysis for predictive testing in NSCLC.

Tissue Acquisition
==================

For a definite diagnosis of lung cancer, it is important to obtain adequate tissue samples and to process these adequately. Minimally invasive techniques can be used to obtain specimens in patients with advanced NSCLC. The available methods for acquisition of tumor cells or tissue are exfoliation cytology, aspiration cytology, and biopsy[@B11].

Exfoliation cytology sampling techniques include bronchial washing, bronchoalveolar lavage, bronchial brushing, and sputum cytology. Aspiration cytology sampling methods include transbronchial needle aspiration (TBNA), endobronchial ultrasound (EBUS), and endoscopic ultrasound; these may be used in conjunction with one or more other techniques. Biopsies used to diagnose lung cancer include bronchial biopsy, transbronchial lung biopsy, and transthoracic needle biopsy[@B11]-[@B13].

The success rates for these procedures vary considerably. The size of needle and forceps and the number of biopsies may affect the accuracy of diagnosis and risk of complications[@B11],[@B14].

Rapid on site examination of TBNA specimens is a fast cytological examination of sample adequacy and allows preliminary diagnosis by a pathologist[@B11],[@B12]. In addition, the telepathology system makes it possible for pathologists to view cytology samples remotely and is a valuable time-saving technology[@B12],[@B15].

Cytology samples obtained by EBUS-TBNA are sufficient for evaluation of *EGFR* mutation and *ALK* rearrangement by molecular testing[@B10],[@B16],[@B17].

The pulmonologist or radiologist who performs a tissue sampling procedure should endeavor to obtain sufficient tissue for diagnosis and molecular analysis. If only limited tissue is acquired, owing to unanticipated technical problems or complications during the procedure, the order of preference for tissue analysis must be considered[@B8],[@B9],[@B12],[@B18].

Pathology Approach
==================

Accurate and relevant clinical information is essential for appropriate handling of small samples from suspected lung cancers in pathology laboratories. Five features providing clinical information relevant to pathology diagnosis are sample site, primary tumor or metastasis, presumptive diagnosis, previous relevant treatment (including surgery, chemotherapy, or radiotherapy), and smoking history[@B11]. Using this information, pathologists must determine priorities for the diagnostic approach and arrange necessary investigations.

Generally, the diagnostic approach to lung cancer workup consists of three steps: 1) identification of malignancy, 2) histologic typing, and 3) molecular analysis as appropriate[@B11].

Reflex testing, a testing policy that does not require a clinician order for each case, may help to assure rapid diagnosis without delay of immunohistochemistry (IHC) and molecular testing. Conversely, this approach may not be optimal if tissue samples are insufficient[@B10],[@B11],[@B18].

In about two thirds of NSCLC cases it is possible to differentiate between squamous cell carcinoma and adenocarcinoma adequately using morphological characteristics. In these cases, immunohistochemial staining is not required and small tissue samples can be preserved for appropriate molecular testing[@B8]-[@B11],[@B18].

In clinical practice, it may not be necessary to perform extensive diagnostic workup, for example in cases where the patient has early stage lung cancer and surgical resection is considered, or if active treatment is refused[@B10],[@B11],[@B18].

Histologic Subtyping
====================

The new classification of lung adenocarcinoma recommends that NSCLC is further identified as a specific histologic type, such as adenocarcinoma or squamous cell carcinoma, whenever possible[@B8]. Adenocarcinoma may manifest glandular differentiation with lepidic (formerly bronchioloalveolar), acinar, papillary, micropapillary, or solid growth patterns, while key morphologic features of squamous cell carcinoma are keratinization, pearl formation, and/or intercelluar bridges[@B9].

The percentage of NSCLC cases that cannot be accurately classified into histologic subtypes can be as high as 40%; such cases are diagnosed as NSCLC-not otherwise specified (NOS)[@B8],[@B9],[@B11]. Recently, it was recommended that the diagnosis of NSCLC-NOS should be reduced to less than 5%, and IHC may be a useful method for refining diagnosis if NSCLCs are poorly differentiated and not clearly differentiated by routine light microscopy[@B8],[@B9],[@B11],[@B12].

Thyroid transcription factor-1 (TTF-1) is the strongest diagnostic marker for adenocarcinoma, while p63 is a reliable marker for squamous cell carcinoma. Currently, TTF-1 and p63 are the two principle markers capable of subtyping NSCLC[@B8],[@B9],[@B11],[@B12]. Mucin stain may also be useful for identifying adenocarcinoma, likewise cytokeratin 5/6 (CK5/6) can be valuable for distinguishing squamous cell carcinoma. Napsin A is a highly specific marker for lung adenocarcinoma and p40 is an antibody that recognizes a specific p63 isoform, and is superior to p63 in specificity, with potential to replace p63 as a marker of squamous cell carcinoma[@B8],[@B9],[@B11],[@B12]. In general, immunohistochemical panels containing TTF-1, p63, CK5/6, mucin stain or TTF-1, p63, CK5/6, and Napsin A are used to subtype poorly differentiated NSCLC[@B19],[@B20]. Again, the IHC tests for histologic subtype should be minimal to preserve as much tissue as possible for molecular analysis from small biopsy and cytology samples[@B8]-[@B11],[@B18].

Specimen Requirements for Molecular Analysis
============================================

The specimen purity, defined by the ratio of malignant cells to \"contaminating\" non-neoplastic cells and necrotic tissue, is crucial for the sensitivity of all molecular methods; therefore, tumor cell enrichment is necessary for molecular tests, such as direct sequencing, which has relatively low sensitivity[@B10],[@B11],[@B14]. This can be performed by demarcating the area of interest in a paraffin block or glass slide and manual macro/microdissection. Laser capture microdissection is rarely necessary in histological specimens, but is sometimes useful for cytological specimens[@B10],[@B11].

DNA quality is primarily influenced by specimen fixation time, the fixation solution used, and the degree of tissue necrosis. Fixation times of 6 to 48 hours are recommended for adequate results. Formalin is the most widely used fixative, although alcohol fixed specimens show comparable results[@B10]-[@B12].

If molecular analyses are performed sequentially, results should be available for *EGFR* and *KRAS* mutation analysis within 5 working days, ALK IHC within 2 working days, and *ALK* fluorescence *in situ* hybridization (FISH) test within 3 working days. The total turnaround time (TAT) for *EGFR* and *ALK* testing should not exceed 2 weeks (10 working days)[@B10],[@B11].

In practice, the duration of the order-to-report time may be delayed by several factors. The communication between clinicians and pathologists in hospital is important and poor collaboration may lead to delayed results. If the hospital is not set up to perform molecular analyses, samples are transported to specialized molecular pathology laboratories and this can also increase the order-to-report time[@B10],[@B11].

Molecular Analysis: Predictive Testing
======================================

1. *EGFR* mutation
------------------

*EGFR* mutation status is the best predictor of response to EGFR-TKI therapy in NSCLC[@B5],[@B6],[@B21]. It is important to determine which patients should be tested for *EGFR* mutations, and which tests should be performed[@B10]. The most common *EGFR* mutations are deletions in exon 19 and the L858R point mutation in exon 21; together these comprise up to 90% of all activating *EGFR* mutations[@B10],[@B22]. However, clinical *EGFR* mutation testing should be able to detect all individual mutations that have been reported with a frequency of at least 1% in *EGFR*-mutated lung adenocarcinomas[@B10]. *EGFR* mutations are significantly more frequent in never smokers, women, East Asians, and adenocarcinomas, but also occur in smokers, men, and Western; therefore, these clinical characteristics are not absolute markers indicating that *EGFR* mutation analysis is necessary[@B10],[@B11].

### 1) Correlations of histologic features with *EGFR* mutations

In adenocarcinoma, the prevalence of *EGFR* mutation is 45% in Pacific Asians and 24% in Caucasians[@B10]. A recent Korean nationwide survey reported that the overall *EGFR* mutation rate was 34.3% in NSCLC and 43.3% in the adenocarcinoma histologic type[@B23].

*EGFR* mutations were significantly associated with adenocarcinoma *in situ*, minimally invasive adenocarcinoma, and lepidic- and papillary-predominant adenocarcinoma subtypes, whereas they were rarely detected in mucinous subtype tumors[@B8],[@B10],[@B24]. *EGFR* mutations have also been found in large cell carcinomas, while the mutation rate in squamous cell carcinoma is generally very low[@B11]. Therefore, *EGFR* mutation testing is recommended for adenocarcinoma, large cell carcinoma, NSCLC-NOS, and squamous cell carcinomas of never smokers and where only small biopsy specimens are available[@B4].

### 2) *EGFR* mutation testing methods

Direct sequencing is widely used for *EGFR* mutation detection and remains the gold standard for gene mutation analysis, although it has low sensitivity. The method requires that at least 50% of assayed cells are malignant, corresponding to mutations in approximately 25% of the total DNA in the sample[@B10],[@B11]. In addition to direct sequencing, various other techniques are used to detect *EGFR* mutations, such as pyrosequencing, Scorpion amplification refractory mutation system, and peptide nucleic acid polymerase chain reaction clamping. These new techniques are more sensitive and rapid than direct sequencing ([Table 1](#T1){ref-type="table"})[@B10],[@B11],[@B25],[@B26].

Recently, *EGFR* mutation-specific antibodies, recognizing the two most common mutations, deletion E746-A750 in exon 19 and the L858R point mutation in exon 21, have been developed and can be used in immunohistochemical staining to identify the expressed mutated EGFR proteins. This technique is fast, inexpensive, and easily available in most pathology laboratories, although it is lacks sufficient sensitivity to be used as standard method. Although *EGFR* mutation-specific IHC is not currently recommended to select candidates for EGFR-TKI therapy, the method could be useful for mutation screening and as a predictive marker for patient management in the future[@B10],[@B11],[@B25],[@B27].

### 3) *EGFR* mutation in cytology samples

In practice, adequate tissue samples for diagnosis are not obtained for all patients with lung cancer. Advanced stage NSCLC is often diagnosed solely using cytology samples.

Cytology samples, such as malignant pleural effusion and fine needle aspirate, are also suitable for *EGFR* mutation testing. Use of cell blocks is preferred to smear preparations, due to the high tumor cell content and preservation of the original specimen. Use of more sensitive mutation testing methods is required when cytology samples with low tumor content are used[@B10],[@B25].

2. *ALK* rearrangement
----------------------

The *ALK* gene rearrangement is a recently identified therapeutic target for tyrosine kinase treatment in NSCLC[@B28]. The *ALK* gene translocation was originally identified in a subset of anaplastic large cell lymphomas. Recently, it was also discovered in NSCLC and the most common *ALK* fusion oncogene partner is the echinoderm microtubule-associated protein-like 4 (*EML4*)[@B10],[@B29].

*EML4-ALK* rearrangement is present in about 4% of all cases of NSCLC[@B30]. It is more frequent in younger patients, never/light smokers, and adenocarcinoma (predominantly solid pattern and signet ring cell subtypes)[@B30],[@B31]. In one study, which focused on patients with adenocarcinoma histology, the frequency of *EML4-ALK* was 22% within the group of never or light smokers and 33% among never or light smokers without *EGFR* mutations[@B32]. This mutation is mutually exclusive with *EGFR* and *KRAS* mutations, with very rare exceptions. Therefore, the guidelines recommend a stepwise-testing algorithm: first, analyses of the most common mutations, *EGFR* and *KRAS*, are performed and, if the results of these are negative, testing for *ALK* rearrangement is undertaken[@B10],[@B11],[@B31].

Currently, FISH, which has been used in clinical trials with crizotinib, is considered the standard technique for detection of *ALK* rearrangement and is also the Food and Drug Administration (FDA)-approved method[@B10],[@B11]. An *ALK* FISH assay, using dual color break-apart probes, is commonly used. With this assay, two FISH probes of different colors (red and green) flank the common breakpoint within *ALK*, separating when a rearrangement occurs. *ALK* rearrangement appears as distinct and separated red and green signals, while non-rearrangement is seen as a fused yellow signal[@B10],[@B30],[@B33]. FISH allows the use of archival fresh frozen paraffin embedded tissue and can detect any fusion partner. However, the technique requires specialized equipment and expertise, is expensive, and has a relatively long TAT[@B10],[@B31],[@B33].

IHC and reverse transcriptase-polymerase chain reaction (RT-PCR) are other diagnostic methods for *ALK* rearrangement. IHC is technically easy, relatively cheap, rapid, and considered as a useful screening method to select candidates for treatment as the *ALK* FISH assay[@B10],[@B31],[@B33]-[@B36]. RT-PCR is also technically easy, rapid, and sensitive; however, this method is only applicable for known fusion partners and it is difficult to obtain high-quality RNA in clinical practice ([Table 2](#T2){ref-type="table"})[@B10],[@B31],[@B33],[@B34].

[Figure 1](#F1){ref-type="fig"} shows a diagnostic algorithm for histologic subtyping and molecular analysis in NSCLC diagnosis.

Conclusion
==========

Recently, the development of new therapeutic agents has led accurate histologic subtyping and molecular predictive testing to be mandatory in NSCLC. In this new diagnostic approach, close communication between pulmonologist, radiologist, pathologist, and oncologist, involved in tissue acquisition, pathology diagnosis, molecular analysis, and treatment decisions is necessary. Specifically, each hospital should have a multidisciplinary strategy to obtain adequate tissue samples, process them in a pathology laboratory, classify them into histologic subtypes, and preserve materials for molecular testing, to ensure fast diagnosis without delay.

Ultimately, we expect therapeutic outcomes in NSCLC to improve with personalized therapy, which is driven by the selection of appropriate treatments based on histologic subtype and molecular status, including *EGFR* mutations and *ALK* rearrangement.

![A diagnostic algorithm for histologic subtyping and molecular analysis in non-small cell lung cancer (NSCLC) diagnosis. SCLC: small cell lung cancer; H&E: hematoxylin and eosin; SQCC: squamous cell carcinoma; ADC: adenocarcinoma; NOS: not otherwise specified; TTF-1: thyroid transcription factor-1; CK: cytokeratin; IHC: immunohistochemistry; EGFR: epidermal growth factor receptor; TKI: thyrosine kinase inhibitor; ALK: anaplastic lymphoma kinase; FISH: fluorescence *in situ* hybridization.](trd-75-181-g001){#F1}

###### 

Methods for *EGFR* mutations testing in NSCLC
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*EGFR*: epidermal growth factor receptor; NSCLC: non-small cell lung cancer; PCR-SSCP: polymerase chain reaction (PCR) plus single-strand conformation polymorphism; q-PCR: quantitative PCR; PCR-RFLP, PCR-restriction fragment length polymorphism; MALDI-TOF MS: matrix-assisted laser desorption/ionization time-of-flight mass spectrometry; dHPLC: denaturing high performance liquid chromatography; ARMS: amplified refractory mutation system; PNA PCR clamp: peptide nucleic acid PCR clamp; SMAP: smart amplification process.

###### 

Pros and cons of ALK detection methods
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ALK: anaplastic lymphoma kinase; FISH: fluorescence *in situ* hybridization; FDA: Food and Drug Administration; IHC: immunohistochemistry; RT-PCR: reverse transcription polymerase chain reaction.
